Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

Naoko Takebe; Lucio Miele; Pamela Jo Harris; Woondong Jeong; Hideaki Bando; Michael Kahn; Sherry X. Yang; S. Percy Ivy

doi:10.1038/nrclinonc.2015.61

journal article Apr 07, 2015

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

Naoko Takebe

Lucio Miele

Pamela Jo Harris Woondong Jeong Hideaki Bando

Michael Kahn Sherry X. Yang S. Percy Ivy

Nature Reviews Clinical Oncology Vol. 12 No. 8 pp. 445-464 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrclinonc.2015.61

Topics

No keywords indexed for this article. Browse by subject →

References

199

[1]

Vermeulen, L., Sprick, M. R., Kemper, K., Stassi, G. & Medema, J. P. Cancer stem cells—old concepts, new insights. Cell Death Differ. 15, 947–958 (2008). 10.1038/cdd.2008.20

[2]

Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells

Ingrid Espinoza, Lucio Miele

Cancer Letters 2013 10.1016/j.canlet.2013.08.027

[3]

Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9

Andrei V. Krivtsov, David Twomey, ZHAOHUI FENG et al.

Nature 2006 10.1038/nature04980

[4]

Stem cells, cancer, and cancer stem cells

Tannishtha Reya, Sean J. Morrison, Michael F. Clarke et al.

Nature 2001 10.1038/35102167

[5]

Pattabiraman, D. R. & Weinberg, R. A. Tackling the cancer stem cells—what challenges do they pose? Nat. Rev. Drug Discov. 13, 497–512 (2014). 10.1038/nrd4253

[6]

Tirino, V. et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 27, 13–24 (2013). 10.1096/fj.12-218222

[7]

Lehmann, C., Jobs, G., Thomas, M., Burtscher, H. & Kubbies, M. Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. Int. J. Oncol. 41, 1932–1942 (2012). 10.3892/ijo.2012.1654

[8]

Karsten, U. & Goletz, S. What makes cancer stem cell markers different? Springerplus 2, 301 (2013). 10.1186/2193-1801-2-301

[9]

Sachs, N. & Clevers, H. Organoid cultures for the analysis of cancer phenotypes. Curr. Opin. Genet. Dev. 24, 68–73 (2014). 10.1016/j.gde.2013.11.012

[10]

Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526 (2012). 10.1038/nature11287

[11]

Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527–530 (2012). 10.1038/nature11344

[12]

Lineage Tracing Reveals Lgr5 + Stem Cell Activity in Mouse Intestinal Adenomas

Arnout G. Schepers, Hugo J. Snippert, Daniel E. Stange et al.

Science 2012 10.1126/science.1224676

[13]

Hoey, T. et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168–177 (2009). 10.1016/j.stem.2009.05.019

[14]

Varnat, F., Siegl-Cachedenier, I., Malerba, M., Gervaz, P. & Ruiz i Altaba, A. Loss of WNT–TCF addiction and enhancement of HH–GLI1 signalling define the metastatic transition of human colon carcinomas. EMBO Mol. Med. 2, 440–457 (2010). 10.1002/emmm.201000098

[15]

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

Louis Vermeulen, Felipe De Sousa E Melo, Maartje van der Heijden et al.

Nature Cell Biology 2010 10.1038/ncb2048

[16]

LaBarge, M. A. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res. 16, 3121–3129 (2010). 10.1158/1078-0432.ccr-09-2933

[17]

Merchant, A. A. & Matsui, W. Targeting Hedgehog—a cancer stem cell pathway. Clin. Cancer Res. 16, 3130–3140 (2010). 10.1158/1078-0432.ccr-09-2846

[18]

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

Naoko Takebe, Pamela J. Harris, Ronald Q. Warren et al.

Nature Reviews Clinical Oncology 2011 10.1038/nrclinonc.2010.196

[19]

Espinoza, I. & Miele, L. Notch inhibitors for cancer treatment. Pharmacol. Ther. 139, 95–110 (2013). 10.1016/j.pharmthera.2013.02.003

[20]

Gomez-del Arco, P. et al. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity 33, 685–698 (2010). 10.1016/j.immuni.2010.11.008

[21]

Murthy, A. et al. Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity 36, 105–119 (2012). 10.1016/j.immuni.2012.01.005

[22]

Gu, J. W. et al. Notch signals in the endothelium and cancer “stem-like” cells: opportunities for cancer therapy. Vasc. Cell 4, 7 (2012). 10.1186/2045-824x-4-7

[23]

Therapeutic modulation of Notch signalling — are we there yet?

Emma R. Andersson, Urban Lendahl

Nature Reviews Drug Discovery 2014 10.1038/nrd4252

[24]

Perumalsamy, L. R., Marcel, N., Kulkarni, S., Radtke, F. & Sarin, A. Distinct spatial and molecular features of notch pathway assembly in regulatory T cells. Sci. Signal. 5, ra53 (2012). 10.1126/scisignal.2002859

[25]

Perumalsamy, L. R., Nagala, M., Banerjee, P. & Sarin, A. A hierarchical cascade activated by non-canonical Notch signaling and the mTOR–Rictor complex regulates neglect-induced death in mammalian cells. Cell Death Differ. 16, 879–889 (2009). 10.1038/cdd.2009.20

[26]

Perumalsamy, L. R., Nagala, M. & Sarin, A. Notch-activated signaling cascade interacts with mitochondrial remodeling proteins to regulate cell survival. Proc. Natl Acad. Sci. USA 107, 6882–6887 (2010). 10.1073/pnas.0910060107

[27]

Raafat, A. et al. Rbpj conditional knockout reveals distinct functions of Notch4/Int3 in mammary gland development and tumorigenesis. Oncogene 28, 219–230 (2009). 10.1038/onc.2008.379

[28]

Sade, H., Krishna, S. & Sarin, A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J. Biol. Chem. 279, 2937–2944 (2004). 10.1074/jbc.m309924200

[29]

Lee, K. S. et al. Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway. Genes Dev. 27, 2642–2647 (2013). 10.1101/gad.225169.113

[30]

Takebe, N., Warren, R. Q. & Ivy, S. P. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 13, 211 (2011). 10.1186/bcr2876

[31]

Deangelo, D. J. et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias [abstract]. J. Clin. Oncol. 24 (Suppl.), a6585 (2006). 10.1200/jco.2006.24.18_suppl.6585

[32]

Pandya, K. et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br. J. Cancer 105, 796–806 (2011). 10.1038/bjc.2011.321

[33]

Abel, E. V. et al. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS ONE 9, e91983 (2014). 10.1371/journal.pone.0091983

[34]

Grudzien, P. et al. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 30, 3853–3867 (2010).

[35]

Hassan, K. A. et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 19, 1972–1980 (2013). 10.1158/1078-0432.ccr-12-0370

[36]

Saito, N. et al. A high Notch pathway activation predicts response to γ-secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells 32, 301–312 (2014). 10.1002/stem.1528

[37]

Messersmith, W. A. et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin. Cancer Res. 21, 60–67 (2015). 10.1158/1078-0432.ccr-14-0607

[38]

Milano, J. et al. Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 82, 341–358 (2004). 10.1093/toxsci/kfh254

[39]

Searfoss, G. H. et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. 278, 46107–46116 (2003). 10.1074/jbc.m307757200

[40]

Wong, G. T. et al. Chronic treatment with the γ-secretase inhibitor LY-411575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876–12882 (2004). 10.1074/jbc.m311652200

[41]

Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

Johan H. van Es, Marielle E. Van Gijn, Orbicia Riccio et al.

Nature 2005 10.1038/nature03659

[42]

Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30, 2307–2313 (2012). 10.1200/jco.2011.39.1540

[43]

Dumortier, A. et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS ONE 5, e9258 (2010). 10.1371/journal.pone.0009258

[44]

Roderick, J. E. et al. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J. Exp. Med. 210, 1311–1329 (2013). 10.1084/jem.20112615

[45]

Real, P. J. & Ferrando, A. A. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 23, 1374–1377 (2009). 10.1038/leu.2009.75

[46]

Yun, J. et al. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis 2, e60 (2013). 10.1038/oncsis.2013.26

[47]

Means-Powell, J. et al. A phase Ib dose escalation trial of RO4929097 (a γ-secretase inhibitor) in combination with exemestane in patients with ER+ metastatic breast cancer [abstract P2-14-04]. Cancer Res. 72 (Suppl.), 280s (2012).

[48]

Albain, K. Combination of Notch inhibitor MK-0752 and endocrine therapy for early stage ERα breast cancer in a pre-surgical window study. Cancer Res. 70 (Suppl.), 113s–114s (2010).

[49]

Tolcher, A. W. et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348–2353 (2012). 10.1200/jco.2011.36.8282

[50]

Harrison, H. et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70, 709–718 (2010). 10.1158/0008-5472.can-09-1681

Showing 50 of 199 references

Cited By

1,107

Expression pattern and clinical significance of β-catenin gene and protein in patients with primary malignant and benign bone tumors

Narges Khademian, Alireza Mirzaei · 2022

Scientific Reports

Targeting Notch in oncology: the path forward

Samarpan Majumder, JUDY S. CRABTREE · 2020

Nature Reviews Drug Discovery

Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells

Lianhua Zhang, Jianjun Sha · 2017

Cell Cycle

Complexity of the Wnt/β‑catenin pathway: Searching for an activation model

Giovane G. Tortelote, Renata R. Reis · 2017

Cellular Signalling

Metrics

1,107

Citations

199

References

Details

Published: Apr 07, 2015
Vol/Issue: 12(8)
Pages: 445-464
License: View

Authors

1National Cancer Institute, Bethesda, MD;

S

S. Percy Ivy

Cite This Article

Naoko Takebe, Lucio Miele, Pamela Jo Harris, et al. (2015). Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature Reviews Clinical Oncology, 12(8), 445-464. https://doi.org/10.1038/nrclinonc.2015.61

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

You May Also Like